Ensavatatug

恩萨妥塔单抗

Report date: 2026/04/16 20:00:17

Base Information

Drug NameEnsavatatug
Drug Alias NamePRTH-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionDiscoidin domain receptor 1 antagonists
TargetsDiscoidin domain receptor 1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe George Washington University Milken Institute School Of Public Health (Gwu)Parthenon Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesIncendia Therapeutics Inc
Inactive CompaniesThe George Washington University Milken Institute School Of Public Health (Gwu)Parthenon Therapeutics Inc
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A